Corporate Profile ::
Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India. It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
Recently it has also forayed into the oncology therapeutic segment while also strengthening its focus on gynecology and pediatric segments. Right from pioneering niche marketing in India to earning the sobriquet of ‘the Company with the most first launches’, Torrent Pharma has always remained ahead of its competition.
Torrent Pharma’s competitive advantage stems from its world-class manufacturing facilities, advanced R&D capabilities, extensive domestic network and a widespread global presence.
It has three world-class manufacturing facilities at Indrad (Gujarat), Baddi (Himachal Pradesh) and Sikkim. The facilities are approved by USFDA, WHO, MHRA, TGA and other global regulatory bodies. A new facility is taking shape at Dahej SEZ in Western India, which will cater to the international markets. Torrent Pharma is the sole manufacturer of Insulin Formulations for Novo Nordisk in India since the early ‘90s and has also set up a dedicated formulation and packaging facility for Insulin.
It is also amongst the few Indian pharma majors to recognize the importance of research and development in the post 2005 GATT era. Its modern and well-equipped R&D Centre is ranked amongst the best in the country and has a team of highly qualified scientists working on various Drug Discovery and Development projects. The R&D Centre has been approved by USFDA and various other regulatory authorities.
The Indian operations of the company are controlled through well-segregated marketing divisions, strategically structured on specific therapeutic areas. Together, these divisions spearhead the company’s dominant position in the various therapeutic segments that it operates in.
Recently Torrent Pharma entered into a definitive binding agreement with Elder Pharma to acquire its branded domestic formulations business in India and Nepal. This will be the largest acquisition by an Indian pharma company in the domestic market and will significantly strengthen its position in the neutraceuticals and women healthcare segments.
Torrent Pharma has a strong international presence spanning over 70 countries across five continents with over 1200 product registrations. It has wholly owned subsidiaries in USA, UK, Germany, Brazil, Russia, Mexico, Philippines Australia and other major markets. These wholly owned subsidiaries spearheads the company’s entry into several new regulated and semi regulated international markets.
Today, Torrent Pharma, with its state of the art manufacturing and research facilities and a global presence, is all poised to carve a niche for itself in the international pharma arena. It is well set on an exciting growth phase in all directions.